down arrow

Disc Medicine, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2546041011
USD
93.79
4.07 (4.54%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

91.2294.58

52 Week

30.8297.11
Valuation
Technical
Day's Volume

CASH

280.44 k

Shareholding (Mar 2025)

FII

9.60%

Held by 80 FIIs

DII

25.2%

Held by 36 DIIs

Promoter

32.73%

How big is Disc Medicine, Inc.?

22-Jun-2025

As of Jun 18, Disc Medicine, Inc. has a market capitalization of 1,733.45 million and reported net sales of 0.00 million with a net profit of -116.50 million over the last four quarters. As of Dec 24, the company has shareholder's funds of 443.59 million and total assets of 496.77 million.

As of Jun 18, Disc Medicine, Inc. has a market capitalization of 1,733.45 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of Net Sales for the latest four quarters is 0.00 million, while the sum of Net Profit for the same period is -116.50 million.<BR><BR>As of Dec 24, the reporting period shows Shareholder's Funds of 443.59 million and Total Assets of 496.77 million.

Read More

What does Disc Medicine, Inc. do?

22-Jun-2025

Disc Medicine, Inc. is a blank check company targeting mergers in the biotechnology sector, currently reporting a net loss of $34 million and a market cap of approximately $1.73 billion. It has no dividend yield and negative return on equity.

Overview: <BR>Disc Medicine, Inc. is a blank check company focused on effecting a merger or similar business combination within the biotechnology sector, classified under the Pharmaceuticals & Biotechnology industry and categorized as a micro-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Profit: -34 Million (Quarterly Results - Mar 2025) <BR>Market cap: USD 1,733.45 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: -1.01 <BR>Return on Equity: -17.64% <BR>Price to Book: 2.62 <BR><BR>Contact Details: <BR>Address: C/O Foresite Capital, 600 Montgomery St, Suite 4500 SAN FRANCISCO CA : 94111 <BR>Tel: 1 415 8774887 <BR>Fax: 1 302 6365454

Read More

Is Disc Medicine, Inc. technically bullish or bearish?

20-Sep-2025

As of September 8, 2025, Disc Medicine, Inc. is in a bullish trend with strong indicators, despite mixed signals from the RSI and KST, and has outperformed the S&P 500 over the past year and three years, but underperformed year-to-date and over five years.

As of 8 September 2025, the technical trend for Disc Medicine, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands are also bullish across both periods. The daily moving averages confirm a bullish trend as well. However, the RSI shows a bearish signal on the monthly timeframe, and the KST indicates a mildly bearish stance monthly, while Dow Theory presents a mixed view with mildly bearish weekly and mildly bullish monthly signals.<BR><BR>In terms of performance, Disc Medicine has outperformed the S&P 500 over the past year with a return of 31.44% compared to the S&P's 17.14%, and significantly over the past three years with a return of 353.84% versus 70.41%. However, it has underperformed over the year-to-date and five-year periods.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 2,152 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.01

stock-summary
Return on Equity

-23.67%

stock-summary
Price to Book

3.50

Revenue and Profits:
Net Sales:
(Quarterly Results - Jun 2025)
Net Profit:
-55 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
52.28%
0%
52.28%
6 Months
97.87%
0%
97.87%
1 Year
44.96%
0%
44.96%
2 Years
68.17%
0%
68.17%
3 Years
5352.91%
0%
5352.91%
4 Years
292.43%
0%
292.43%
5 Years
-6.67%
0%
-6.67%

Disc Medicine, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Disc Medicine, Inc. technically bullish or bearish?

As of 8 September 2025, the technical trend for Disc Medicine, Inc. has changed from mildly bullish to bullish. The current stance is bullish with strong indicators supporting this view. The MACD is bullish on both the weekly and monthly time frames, and Bollinger Bands are also bullish across both periods. The daily moving averages confirm a bullish trend as well. However, the RSI shows a bearish signal on the monthly timeframe, and the KST indicates a mildly bearish stance monthly, while Dow Theory presents a mixed view with mildly bearish weekly and mildly bullish monthly signals. In terms of performance, Disc Medicine has outperformed the S&P 500 over the past year with a return of 31.44% compared to the S&P's 17.14%, and significantly over the past three years with a return of 353.84% versus 70.41%. However, it has underperformed over the year-to-date and five-year periods....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
0
EBIT Growth (5y)
-231.81%
EBIT to Interest (avg)
-70.07
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-1.01
Sales to Capital Employed (avg)
0
Tax Ratio
0.40%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.62
EV to EBIT
-7.72
EV to EBITDA
-7.73
EV to Capital Employed
-201.58
EV to Sales
NA
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-17.64%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
Bearish
Bearish
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
Bullish
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 43 Schemes (32.47%)

Foreign Institutions

Held by 80 Foreign Institutions (9.6%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is -109.09% vs -66.04% in Jun 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-61.30",
          "val2": "-30.70",
          "chgp": "-99.67%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-55.20",
          "val2": "-26.40",
          "chgp": "-109.09%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -43.19% vs -63.25% in Dec 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-129.60",
          "val2": "-91.00",
          "chgp": "-42.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.60",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-1.50",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-109.40",
          "val2": "-76.40",
          "chgp": "-43.19%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "0.00%",
          "val2": "0.00%",
          "chgp": "NA",
          "chgp_class": "neutral"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-61.30
-30.70
-99.67%
Interest
0.90
0.00
Exceptional Items
0.00
0.00
Consolidate Net Profit
-55.20
-26.40
-109.09%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in quarter ended Jun 2025 is 0.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is -109.09% vs -66.04% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.00
0.00
Operating Profit (PBDIT) excl Other Income
-129.60
-91.00
-42.42%
Interest
0.60
0.00
Exceptional Items
0.00
-1.50
100.00%
Consolidate Net Profit
-109.40
-76.40
-43.19%
Operating Profit Margin (Excl OI)
0.00%
0.00%
NA
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -43.19% vs -63.25% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Disc Medicine, Inc. stock-summary
stock-summary
Disc Medicine, Inc.
Pharmaceuticals & Biotechnology
FS Development Corp. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company focuses for target business in the biotechnology sector. The Company has no business operations and has not generated any revenues.
Company Coordinates stock-summary
Company Details
C/O Foresite Capital, 600 Montgomery St, Suite 4500 SAN FRANCISCO CA : 94111
stock-summary
Tel: 1 415 8774887
stock-summary
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."